Radiological and inflammatory outcome in severe covid-19 patients received tocilizumab versus high dose of methylprednisolone
kamel, A., Arafat, W., Al –sharawy, L. (2022). Radiological and inflammatory outcome in severe covid-19 patients received tocilizumab versus high dose of methylprednisolone. EKB Journal Management System, 3(4), 99-113. doi: 10.21608/ejmr.2022.267673
Asmaa N. kamel; Waleed R. Arafat; Laila A. Al –sharawy. "Radiological and inflammatory outcome in severe covid-19 patients received tocilizumab versus high dose of methylprednisolone". EKB Journal Management System, 3, 4, 2022, 99-113. doi: 10.21608/ejmr.2022.267673
kamel, A., Arafat, W., Al –sharawy, L. (2022). 'Radiological and inflammatory outcome in severe covid-19 patients received tocilizumab versus high dose of methylprednisolone', EKB Journal Management System, 3(4), pp. 99-113. doi: 10.21608/ejmr.2022.267673
kamel, A., Arafat, W., Al –sharawy, L. Radiological and inflammatory outcome in severe covid-19 patients received tocilizumab versus high dose of methylprednisolone. EKB Journal Management System, 2022; 3(4): 99-113. doi: 10.21608/ejmr.2022.267673

Radiological and inflammatory outcome in severe covid-19 patients received tocilizumab versus high dose of methylprednisolone

Egyptian Journal of Medical Research
Volume 3, Issue 4, October 2022, Page 99-113  XML PDF (668.6 K)
Document Type: Original Article
DOI: 10.21608/ejmr.2022.267673
View on SCiNiTO View on SCiNiTO
Authors
Asmaa N. kamel; Waleed R. Arafat; Laila A. Al –sharawy
Chest Department, Faculty of Medicine, Beni-Suef University, Egypt
Abstract
Background: Cytokine storm causes ARDS, multiple organ failure and post covid-19 pulmonary sequale so anti-inflammatory drugs as tocilizumab and methylprednisolone are widely used to treat covid-19 patients. Methods: prospective observational study on 60 covid-19  patients >18 years old. Diagnosis of covid-19 infection was based on World Health Organization (WHO) criteria and confirmed by nasal and pharyngeal swab for real time reverse transcriptase polymerase chain reaction analysis. 30 hypoxemic covid-19 who received tocilizumab and 30 hypoxemic covid-19 patients who received high dose of methylprednisolone.then Comparison of both groups regarding duration of admission, length of Oxygen need, resolution of CT findings and inflammatory marker levels. Results: There was no significant difference ( p-value >0.05) between the two treatment protocols as regards CT findings at time of admission and after a month from discharge. On admission, Higher mean of CRP, D-dimer and a lower mean of procalcitonine were noted   among the group treated with Tocilizumab protocol while significantly lower mean of ferritin (p-value <0.05) .After one month follow up there was no difference in CRP level between the two groups. Also there was no statistical significant difference between the two groups regarding hospital stay and length of oxygen therapy between the two groups. Conclusion: lower ferritin and higher D-Dimer were noted in tocilizumab treated group while no difference in radiological finding or length  of hospital stay between the two groups
 
Keywords
Covid-19; Tocilizumab CT; Methylprednisolone; hospital stay
References
  1. Vieira LMF., Emery E. and AndrioloA. COVID-19: laboratory diagnosis for clinicians. An updating article. Sao Paulo Medical Journal [online]. 2020, v. 138, n. 03.
  2. Horby P., Lim WS, Emberson JR, et al. RECOVERY Collaborative Group Dexamethasone in hospitalized patients with Covid-19 - Preliminary report. N Engl J Med.  
  3. Ramiro S., Mostard RLM, Magro-Checa C., et al. Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome : Results of the CHIC study. Ann Rheum Dis. 2020; 79 : 1143-1151. 
  4. National Institute for Health Care Excellence (NICE) in collaboration with NHS England and NHS Improvement. Managing COVID-19 symptoms (including at the end of life) in the community: summary of NICE guidelines. BMJ. 2020;369:m1461.
  5. Gubernatorova EO., Gorshkova EA., Polinova AI., et al. IL-6: relevance for immunopathology of SARS-CoV-2. Cytokine Growth Factor Rev. 2020;53:13–24.
  6. Sackett K., Cunderlik M., Sahni N., et al. Extreme hyperferritinemia: causes and impact on diagnostic reasoning. Am. J. Clin. Pathol. 2016;145:646–650.
  7. Sudre C, Murray B, Varsavsky T, et al. Attributes and predictors of long-COVID: analysis of COVID cases and their symptoms collected by the Covid Symptoms Study App. medRxiv 2020; published online Oct 21.
  8. Coomes EA., medRxiv Haghbayan H. 2020. Interleukin-6 in COVID-19: A Systematic Review and Meta-Analysis. March 30.
  9. Herold Tobias, Jurinovic Vindi, Arnreich Chiara, et al. medRxiv. 2020
  10. Fadel R., Morrison AR., Vahia A., et al. Early short course corticosteroids in hospitalized patients with COVID-19. Clin Infect Dis. 2020; 71:2114–2120.
  11. Guaraldi G., Marianna Meschiari M., Cozzi-Lepri A., et al. Tocilizumab in patients with severe COVID-19: A retrospective cohort study. Lancet Rheumatol. 2020;2:e474–e484
  12. Stone JH., Frigault MJ., Serling-Boyd NJ., et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020;383:2333–2344.
  13. Abani O., Abbas A., Abbas F., et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397:1637–1645.
  14. Horby PW., Pessoa-Amorim G., Peto L., et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. Lancet. 2021.
  15. Bonanad Clara  , Sergio García-Blas  , Francisco Tarazona-Santabalbina ,  et al. The Effect of Age on Mortality in Patients With COVID-19: A Meta-Analysis With 611,583 Subjects. J Am Med Dir Assoc. 2020 ;21(7):915-918.
  16. Ahmed A., Ali A., & Hasan S. . Comparison of epidemiological variations in COVID-19 patients inside and outside of China—a meta-analysis2020. Frontiers in public health, 8, 193.
  17. Yang J., Zheng Y., GouX., et al. Prevalence of comorbidities and its effects in coronavirus disease 2019 patient: A systematic review and meta-analysis. Int J Infect Dis2020, 94, 91-95.‏
  18. Lauer SA , Grantz KH , Bi Q , et al.The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application . Annals of Internal Medicine . 2020. ; 172 ( 9 ): 577 – 82.
  19. Abate SM , Ahmed Ali S , Mantfardo B , Basu B . Rate of Intensive Care Unit admission and outcomes among patients with coronavirus: A systematic review and Meta-analysis . PLOS ONE . 2020. ; 15 ( 7).
  20. Keske Ş., Tekin S., Sait B., et al. Appropriate use of tocilizumab in COVID-19 infection. Int. J. Infect. Dis. 2020 Oct;99:338–343.
  21. Cherry JD , Krogstad P . SARS: The First Pandemic of the 21st Century . Pediatric Research . 2004. ; 56 ( 1 ): 1 – 5 .
  22. Ooi GC KP , Muller NL , Yiu WC , et al . Severe acute respiratory syndrome: temporal lung changes at thin-section CT in 30 patients . Radiology . 2004. ; 230 : 836 – 44 .
  23. Antonio GE WK , Hui DS , Wu A , et al . Thin-Section CT in Patients with Severe Acute Respiratory Syndrome Following Hospital Discharge: Preliminary Experience . Radiology . 2003. ; 228 : 810 – 5 .
  24. Fabbri L , Moss S , Khan F, et al. . Post-viral parenchymal lung disease of COVID-19 and viral pneumonitis: A systematic review and meta-analysis . medRxiv . 2021.
  25. Aomar-Millán IF, Salvatierra J, Torres-Parejo Úet al. Glucocorticoids alone versus tocilizumab alone or glucocorticoids plus tocilizumab in patients with severe SARS-CoV-2 pneumonia and mild inflammation. Med Clin (Barc). 2021 Jun 25;156(12):602-605.
  26. M,  Xu.X,  Xia.D,  et al.Effects of corticosteroid treatment for non-severe COVID-19 pneumonia: a propensity score-based analysis Shock 2020.
  27. Pinzón M.A., Ortiz S., Holguín H.,  et al. Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia. PLoS One. 2021 May 25;16(5):e0252057.
Statistics
Article View: 104
PDF Download: 132